ABCELLERA BIOLOGICS INC (ABCL)
CA00288U1066 - Common Stock
Taking everything into account, ABCL scores 3 out of 10 in our fundamental rating. ABCL was compared to 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability. ABCL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ABCL has reported negative net income.
ABCL had a negative operating cash flow in the past year.
In multiple years ABCL reported negative net income over the last 5 years.
Of the past 5 years ABCL 4 years had a positive operating cash flow.
1.2 Ratios
ABCL has a Return On Assets (-10.85%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -13.80%, ABCL is in line with its industry, outperforming 58.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.85% | ||
| ROE | -13.8% | ||
| ROIC | N/A |
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABCL has been increased compared to 1 year ago.
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ABCL has an Altman-Z score of 1.79. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
ABCL has a Altman-Z score (1.79) which is comparable to the rest of the industry.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.79 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
ABCL has a Current Ratio of 10.96. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.96, ABCL belongs to the best of the industry, outperforming 92.73% of the companies in the same industry.
A Quick Ratio of 10.96 indicates that ABCL has no problem at all paying its short term obligations.
ABCL has a Quick ratio of 10.96. This is amongst the best in the industry. ABCL outperforms 92.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.96 | ||
| Quick Ratio | 10.96 |
3. Growth
3.1 Past
ABCL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.00%.
Looking at the last year, ABCL shows a very negative growth in Revenue. The Revenue has decreased by -77.23% in the last year.
Measured over the past years, ABCL shows a very strong growth in Revenue. The Revenue has been growing by 34.00% on average per year.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)-77.23%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Sales Q2Q%-27.18%
3.2 Future
Based on estimates for the next years, ABCL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.32% on average per year.
ABCL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.72% yearly.
EPS Next Y-13.77%
EPS Next 2Y-16.17%
EPS Next 3Y-8.3%
EPS Next 5Y15.32%
Revenue Next Year-11.88%
Revenue Next 2Y12.92%
Revenue Next 3Y30.56%
Revenue Next 5Y18.72%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ABCL's earnings are expected to decrease with -8.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.17%
EPS Next 3Y-8.3%
5. Dividend
5.1 Amount
No dividends for ABCL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ABCELLERA BIOLOGICS INC
NASDAQ:ABCL (11/4/2024, 9:56:16 AM)
2.765
+0.04 (+1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap814.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.85% | ||
| ROE | -13.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.96 | ||
| Quick Ratio | 10.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-13.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.23%
Revenue growth 3Y-45.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y